Advertisement
Roche
Roche

Revascularization benefits

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-te

July 6, 2000

New York, July 5, 2000 (Praxis Press) The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial show a reduction in the composite endpoint of death or myocardial infarction, contradicting previous large-scale randomized trials. The recent one-year follow-up of this randomized trial published in the Lancet confirms that the invasive strategy rapidly transforms unstable coronary-artery disease into a stable condition, lowering long-term mortality and reintervention rate, myocardial-infarction risk, and the recurrence of angina and ischemia (see paper). Compared with non-invasive treatment strategy in 100 patients, the invasive approach saves 1.7 lives, prevents 2.0 non-fatal myocardial infarctions, and 20 re-admissions. These findings strongly suggest revascularization as the treatment of choice for most patients with unstable CAD with ischemia, or biochemical markers of myocardial damage.

Advertisement
The Scientist
The Scientist

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Mettler Toledo
Mettler Toledo
Advertisement
The Scientist
The Scientist
Life Technologies